ARF6 inhibition stabilizes the vasculature and enhances survival During endotoxic shock

Journal of Immunology

Volumn 192, Issue 12, 2014, Pages 6045-6052

  Davis, Chadwick T ^a   Zhu, Weiquan ^a   Gibson, Christopher C ^a,b   Bowman Kirigin, Jay A ^a   Sorensen, Lise ^a   Ling, Jing ^a   Sun, Huiming ^a,c   Navankasattusas, Sutip ^a   Li, Dean Y ^a,d,e  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b University of Utah   (United States)

^c NANJING UNIVERSITY   (China)

^d Sichuan Academy of Medical Sciences   (China)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE RIBOSYLATION FACTOR 6; GUANINE NUCLEOTIDE EXCHANGE FACTOR; MYELOID DIFFERENTIATION FACTOR 88;

AMINO TERMINAL SEQUENCE; ARTICLE; CELL MEMBRANE PERMEABILITY; CONTROLLED STUDY; CYTOKINE RESPONSE; ENDOTHELIUM CELL; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEPTIC SHOCK; SIGNAL TRANSDUCTION; SURVIVAL; VASCULARIZATION;

ADHERENS JUNCTIONS; ADP-RIBOSYLATION FACTORS; ANIMALS; CAPILLARY PERMEABILITY; CELLS, CULTURED; ENDOTHELIAL CELLS; FEMALE; GTPASE-ACTIVATING PROTEINS; HUMANS; LIPOPOLYSACCHARIDES; MALE; MICE; MYELOID DIFFERENTIATION FACTOR 88; SHOCK, SEPTIC; SIGNAL TRANSDUCTION;

EID: 84902156978     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1400309     Document Type: Article

References (50)

1. London, N. R., W. Zhu, F. A. Bozza, M. C. Smith, D. M. Greif, L. K. Sorensen, L. Chen, Y. Kaminoh, A. C. Chan, S. F. Passi, et al. 2010. Targeting Robo4-Dependent Slit Signaling to Survive the Cytokine Storm in Sepsis and Influenza. Sci. Transl. Med. 2:23ra19.
2. Cohen, J. 2002. The immunopathogenesis of sepsis. Nature 420:885-891.
3. Lee, W. L., and A. S. Slutsky. 2010. Sepsis and endothelial permeability. N. Engl. J. Med. 363:689-691.
4. Dellinger, R. P., M. M. Levy, A. Rhodes, D. Annane, H. Gerlach, S. M. Opal, J. E. Sevransky, C. L. Sprung, I. S. Douglas, R. Jaeschke, et al; Surviving Sepsis Campaign Guidelines Committee including The Pediatric Subgroup. 2013. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med. 39:165-228.
5. Annane, D., P. Aegerter, M. C. Jars-Guincestre, and B. Guidet; CUB-Réa Network. 2003. Current epidemiology of septic shock: the CUB-Réa Network. Am. J. Respir. Crit. Care Med. 168:165-172.
6. Angus, D. C., and T. Van Der Poll. 2013. Severe sepsis and septic shock. N. Engl. J. Med. 369:840-851.
7. Riedemann, N. C., R. F. Guo, and P. A. Ward. 2003. Novel strategies for the treatment of sepsis. Nat. Med. 9:517-524.
8. Annane, D. 2011. Corticosteroids for severe sepsis: an evidence-based guide for physicians. Ann. Intensive care 1:7.
9. Opal, S. M., P. F. Laterre, B. Francois, S. P. La Rosa, D. C. Angus, J. P. Mira, X. Wittebole, T. Dugernier, D. Perrotin, M. Tidswell, et al; ACCESS Study Group. 2013. Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial. JAMA 309:1154-1162.
10. Reinhart, K., and W. Karzai. 2001. Anti-tumor necrosis factor therapy in sepsis: update on clinical trials and lessons learned. Crit. Care Med. 29 (7, Suppl.) S121-S125.
11. Opal, S. M., C. J. Fischer, Jr., J. F. Dhainaut, J. L. Vincent, R. Brase, S. F. Lowry, J. C. Sadoff, G. J. Slotman, H. Levy, R. A. Balk, et al 1997. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit. Care Med. 25:1115-1124.
12. Tracey, K. J., Y. Fong, D. G. Hesse, K. R. Manogue, A. T. Lee, G. C. Kuo, S. F. Lowry, and A. Cerami. 1987. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 330:662-664.
13. Van Der Poll, T., and S. M. Opal. 2008. Host-pathogen interactions in sepsis. Lancet Infect. Dis. 8:32-43.
14. Warner, N., and G. Núñez. 2013. MyD88: a critical adaptor protein in innate immunity signal transduction. J. Immunol. 190:3-4.
15. Zhu, W., N. R. London, C. C. Gibson, C. T. Davis, Z. Tong, L. K. Sorensen, D. S. Shi, J. Guo, M. C. Smith, A. H. Grossmann, et al. 2012. Interleukin receptor activates a MYD88-ARNO-ARF6 cascade to disrupt vascular stability. Nature 492:252-255.
16. Martins-Green, M., M. Petreaca, and M. Yao. 2008. An assay system for in vitro detection of permeability in human "endothelium." Methods Enzymol. 443:137-153.
17. Gavard, J., and J. S. Gutkind. 2006. VEGF controls endothelial-cell permeability by promoting the beta-arrestin-dependent endocytosis of VE-cadherin. Nat. Cell Biol. 8:1223-1234.
18. Moake, J. L., N. A. Turner, N. A. Stathopoulos, L. Nolasco, and J. D. Hellums. 1988. Shear-induced platelet aggregation can be mediated by vWF released from platelets, as well as by exogenous large or unusually large vWF multimers, requires adenosine diphosphate, and is resistant to aspirin. Blood 71:1366-1374.
19. Wilson, B. D., C. C. Gibson, L. K. Sorensen, M. Y. Guilhermier, M. Clinger, L. L. Kelley, Y.-T. E. Shiu, and D. Y. Li. 2011. Novel approach for endothelializing vascular devices: understanding and exploiting elastin-endothelial interactions. Ann. Biomed. Eng. 39:337-346.
20. Zimmerman, G. A., T. M. McIntyre, and S. M. Prescott. 1985. Thrombin stimulates the adherence of neutrophils to human endothelial cells in vitro. J. Clin. Invest. 76:2235-2246.
21. Yost, C. C., M. M. Denis, S. Lindemann, F. J. Rubner, G. K. Marathe, M. Buerke, T. M. McIntyre, A. S. Weyrich, and G. A. Zimmerman. 2004. Activated polymorphonuclear leukocytes rapidly synthesize retinoic acid receptor-alpha: a mechanism for translational control of transcriptional events. J. Exp. Med. 200:671-680.
22. Milnor, W. R. 1982. Hemodynamics. Williams and Wilkins, Baltimore.
23. Radu, M., and J. Chernoff. 2013. An in vivo assay to test blood vessel permeability. J. Vis. Exp. 16:e50062.
24. Han, E. D., R. C. MacFarlane, A. N. Mulligan, J. Scafidi, and A. E. Davis, III. 2002. Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor. J. Clin. Invest. 109:1057-1063.
25. Adam, A. P., A. L. Sharenko, K. Pumiglia, and P. A. Vincent. 2010. Src-induced tyrosine phosphorylation of VE-cadherin is not sufficient to decrease barrier function of endothelial monolayers. J. Biol. Chem. 285:7045-7055.
26. Fitzner, N., S. Clauberg, F. Essmann, J. Liebmann, and V. Kolb-Bachofen. 2008. Human skin endothelial cells can express all 10 TLR genes and respond to respective ligands. Clin. Vaccine Immunol. 15:138-146.
27. Zhao, H., A. R. Anand, and R. K. Ganju. 2014. Slit2-Robo4 pathway modulates lipopolysaccharide-induced endothelial inflammation and its expression is dysregulated during endotoxemia. J. Immunol. 192:385-393.
28. Faure, E., O. Equils, P. A. Sieling, L. Thomas, F. X. Zhang, C. J. Kirschning, N. Polentarutti, M. Muzio, and M. Arditi. 2000. Bacterial lipopolysaccharide activates NF-kappaB through toll-like receptor 4 (TLR-4) in cultured human dermal endothelial cells. Differential expression of TLR-4 and TLR-2 in endothelial cells. J. Biol. Chem. 275:11058-11063.
29. El Azreq, M.-A., V. Garceau, D. Harbour, C. Pivot-Pajot, and S. G. Bourgoin. 2010. Cytohesin-1 regulates the Arf6-phospholipase D signaling axis in human neutrophils: impact on superoxide anion production and secretion. J. Immunol. 184:637-649.
30. Morishige, M., S. Hashimoto, E. Ogawa, Y. Toda, H. Kotani, M. Hirose, S. Wei, A. Hashimoto, A. Yamada, H. Yano, et al. 2008. GEP100 links epidermal growth factor receptor signalling to Arf6 activation to induce breast cancer invasion. Nat. Cell Biol. 10:85-92.
31. Grossmann, A. H., J. H. Yoo, J. Clancy, L. K. Sorensen, A. Sedgwick, Z. Tong, K. Ostanin, A. Rogers, K. F. Grossmann, S. R. Tripp, et al. 2013. The small GTPase ARF6 stimulates b-catenin transcriptional activity during WNT5Amediated melanoma invasion and metastasis. Sci. Signal. 6: ra14.
32. Janssens, S., and R. Beyaert. 2002. A universal role for MyD88 in TLR/IL-1Rmediated signaling. Trends Biochem. Sci. 27:474-482.
33. Clark, K., L. Plater, M. Peggie, and P. Cohen. 2009. Use of the pharmacological inhibitor BX795 to study the regulation and physiological roles of TBK1 and IkappaB kinase epsilon: a distinct upstream kinase mediates Ser-172 phosphorylation and activation. J. Biol. Chem. 284:14136-14146.
34. Kishore, N., C. Sommers, S. Mathialagan, J. Guzova, M. Yao, S. Hauser, K. Huynh, S. Bonar, C. Mielke, L. Albee, et al. 2003. A selective IKK-2 inhibitor blocks NF-kappa B-dependent gene expression in interleukin-1 beta-stimulated synovial fibroblasts. J. Biol. Chem. 278:32861-32871.
35. Mehta, D., and A. B. Malik. 2006. Signaling mechanisms regulating endothelial permeability. Physiol. Rev. 86:279-367.
36. Choi, W., Z. A. Karim, and S. W. Whiteheart. 2006. Arf6 plays an early role in platelet activation by collagen and convulxin. Blood 107:3145-3152.
37. Randazzo, P. A., T. Terui, S. Sturch, H. M. Fales, A. G. Ferrige, and R. A. Kahn. 1995. The myristoylated amino terminus of ADP-ribosylation factor 1 is a phospholipid- and GTP-sensitive switch. J. Biol. Chem. 270:14809-14815.
38. Komarova, Y., and A. B. Malik. 2010. Regulation of endothelial permeability via paracellular and transcellular transport pathways. Annu. Rev. Physiol. 72:463-493.
39. Gavard, J., V. Patel, and J. S. Gutkind. 2008. Angiopoietin-1 prevents VEGFinduced endothelial permeability by sequestering Src through mDia. Dev. Cell 14:25-36.
40. Jones, C. A., N. Nishiya, N. R. London, W. Zhu, L. K. Sorensen, A. C. Chan, C. J. Lim, H. Chen, Q. Zhang, P. G. Schultz, et al. 2009. Slit2-Robo4 signalling promotes vascular stability by blocking Arf6 activity. Nat. Cell Biol. 11:1325-1331.
41. Kagan, J. C., and R. Medzhitov. 2006. Phosphoinositide-mediated adaptor recruitment controls Toll-like receptor signaling. Cell 125:943-955.
42. Van Acker, T., S. Eyckerman, L. Vande Walle, S. Gerlo, M. Goethals, M. Lamkanfi, C. Bovijn, J. Tavernier, and F. Peelman. 2014. The small GTPase Arf6 is essential for the Tram/Trif pathway in TLR4 signaling. J. Biol. Chem. 17:1364-1376.
43. Svensson, H. G., M. A. West, P. Mollahan, A. R. Prescott, R. Zaru, and C. Watts. 2008. A role for ARF6 in dendritic cell podosome formation and migration. Eur. J. Immunol. 38:818-828.
44. Suzuki, T., Y. Kanai, T. Hara, J. Sasaki, T. Sasaki, M. Kohara, T. Maehama, C. Taya, H. Shitara, H. Yonekawa, et al. 2006. Crucial role of the small GTPase ARF6 in hepatic cord formation during liver development. Mol. Cell. Biol. 26:6149-6156.
45. Hafner, M., A. Schmitz, I. Grüne, S. G. Srivatsan, B. Paul, W. Kolanus, T. Quast, E. Kremmer, I. Bauer, and M. Famulok. 2006. Inhibition of cytohesins by SecinH3 leads to hepatic insulin resistance. Nature 444:941-944.
46. Hashimoto, A., S. Hashimoto, R. Ando, K. Noda, E. Ogawa, H. Kotani, M. Hirose, T. Menju, M. Morishige, T. Manabe, et al. 2011. GEP100-Arf6-AMAP1- cortactin pathway frequently used in cancer invasion is activated by VEGFR2 to promote angiogenesis. PLoS ONE 6:e23359.
47. Kanamarlapudi, V., S. E. Owens, K. Saha, R. J. Pope, and S. J. Mundell. 2012. ARF6-dependent regulation of P2Y receptor traffic and function in human platelets. PLoS ONE 7:e43532.
48. Chodobski, A., B. J. Zink, and J. Szmydynger-Chodobska. 2010. Blood-brain barrier pathophysiology in traumatic brain injury. Transl. Stroke Res. 2:492-516.
49. Van Vliet, E. A., S. Da Costa Araújo, S. Redeker, R. Van Schaik, E. Aronica, and J. A. Gorter. 2007. Blood-brain barrier leakage may lead to progression of temporal lobe epilepsy. Brain 130:521-534.
50. Minagar, A., and J. S. Alexander. 2003. Blood-brain barrier disruption in multiple sclerosis. Mult. Scler. 9:540-549